Ernexa Therapeutics (ERNAW) Non Operating Income (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 15 years of Non Operating Income data on file, last reported at $44000.0 in Q1 2026.

• Quarterly Non Operating Income rose 100.81% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 148.25% YoY) and the FY2025 annual result came in at -$27000.0, up 99.6% from the prior year.
• Non Operating Income slipped to $44000.0 in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $19.0 million in Q4 2024 to a low of -$24.3 million in Q3 2024.
• A 5-year average of $87235.3 and a median of -$94000.0 in 2023 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income jumped 14658.33% — and 2024, when it sank 25786.17%.
• Tracing ERNAW's Non Operating Income over 5 years: stood at $288000.0 in 2022, then slumped by 236.11% to -$392000.0 in 2023, then jumped by 4955.1% to $19.0 million in 2024, then sank by 72.08% to $5.3 million in 2025, then tumbled by 99.17% to $44000.0 in 2026.
• The last three Non Operating Income figures came in at $44000.0 (Q1 2026), $5.3 million (Q4 2025), and $759000.0 (Q3 2025), per Business Quant data.